Search

Romosozumab

Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months

Chlorquinaldol

Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Pancrelipase

[L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

Benzhydrocodone

It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

Islatravir

[A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency. … [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently

Phenylbutyric acid

Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation.

Forigerimod

Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.

Benserazide

A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the

Pinacidil

This drug has been discontinued by the FDA. … Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance.